Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $63,403.37 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 7,037 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $63,403.37. Following the completion of the sale, the insider directly owned 144,963 shares in the company, valued at approximately $1,306,116.63. This represents a 4.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Up 1.9%

Shares of Artiva Biotherapeutics stock opened at $7.99 on Friday. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $14.53. The stock has a market cap of $197.51 million, a price-to-earnings ratio of -2.26 and a beta of 2.86. The company’s fifty day moving average is $8.40 and its 200 day moving average is $5.70.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Cantor Fitzgerald upped their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, Wedbush upped their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC boosted its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Renaissance Technologies LLC boosted its position in Artiva Biotherapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after acquiring an additional 37,053 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Artiva Biotherapeutics during the 4th quarter worth about $341,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.